Advertisement

Topics

Daiichi drug hits mark in shingles pain, but misses in other indications

08:30 EDT 30 Jun 2017 | PMLIVE

ALDAY trial shows mirogabalin was unable to reduce pain for fibromyalgia patients

Original Article: Daiichi drug hits mark in shingles pain, but misses in other indications

NEXT ARTICLE

More From BioPortfolio on "Daiichi drug hits mark in shingles pain, but misses in other indications"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Fibromyalgia
FMS (fibromyalgia syndrome) is a widespread idiopathic musculoskeletal pain and fatigue disorder, which is chronic. The pain comes from connective tissues, such as muscles, tendons, and ligaments, but not joints and patients describe it as an ache all ov...